A RISK OF MALIGNANCY INDEX INCORPORATING CA-125, ULTRASOUND AND MENOPAUSAL STATUS FOR THE ACCURATE PREOPERATIVE DIAGNOSIS OF OVARIAN-CANCER

被引:699
作者
JACOBS, I
ORAM, D
FAIRBANKS, J
TURNER, J
FROST, C
GRUDZINSKAS, JG
机构
[1] LONDON HOSP,COLL MED,ACAD UNIT OBSTET & GYNAECOL,LONDON E1 1BB,ENGLAND
[2] ST BARTHOLOMEWS HOSP,COLL MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1A 7BE,ENGLAND
[3] LONDON HOSP,DEPT MED PHYS,LONDON E1 1BB,ENGLAND
来源
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 1990年 / 97卷 / 10期
关键词
D O I
10.1111/j.1471-0528.1990.tb02448.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Summary. Age, ultrasound score, menopausal status, a clinical impression score and serum CA 125 level were assessed to see how they could best distinguish between patients with benign (n = 101) and malignant (n – 42) pelvic masses. Each criteria used alone provided statistically significant discrimination. The most useful individual criteria were a serum CA 125 level of 30 U/ml (sensitivity 81 %, specificity 75%) and an ultrasound score of 2 (sensitivity 71%, specificity 83%). Three criteria could be combined in a risk of malignancy index (RMI) which is simply calculated using the product of the serum CA 125 level (U/ml), the ultrasound scan result (expressed as a score of 0, 1 or 3) and the menopausal status (1 if premenopausal and 3 if postmenopausal). This index was statistically virtually as effective a discriminant between cancer and benign lesions as more formal methods. Using an RMI cut‐off level of 200, the sensitivity was 85% and the specificity was 97%. Patients with an RMT score of greater than 200 had, on average, 42 times the background risk of cancer and those with a lower value 0.15 times the background risk. Copyright © 1990, Wiley Blackwell. All rights reserved
引用
收藏
页码:922 / 929
页数:8
相关论文
共 19 条
[1]   TRANS-VAGINAL COLOR FLOW IMAGING - A POSSIBLE NEW SCREENING TECHNIQUE FOR OVARIAN-CANCER [J].
BOURNE, T ;
CAMPBELL, S ;
STEER, C ;
WHITEHEAD, MI ;
COLLINS, WP .
BRITISH MEDICAL JOURNAL, 1989, 299 (6712) :1367-1370
[2]  
DELAND M, 1979, SURG GYNECOL OBSTET, V148, P346
[3]  
DI-XIA C, 1988, Obstetrics and Gynecology, V72, P23
[4]  
EINHORN N, 1986, OBSTET GYNECOL, V67, P414
[5]  
GADDUCCI A, 1988, EUR J GYNAECOL ONCOL, V5, P373
[6]  
GRIFFITHS CT, 1987, OVARIAN CANCER WAY A, P235
[7]  
HACKER NF, 1987, OVARIAN CANC WAY AHE, P245
[8]  
HERRMANN UJ, 1987, OBSTET GYNECOL, V69, P777
[9]  
JACOBS I, 1988, LANCET, V1, P268
[10]  
JACOBS I, 1989, HUM REPROD, V4, P1